Jared Fennell, Eli Lilly and Company - Qepler Summits And Conferences

Jared Fennell

Senior Scientist
Eli Lilly and Company
Indiana, United States
Lilly's purpose has never been more important. For more than 140 years, we’ve united caring with discovery to create medicines that make life better.

Jared completed his doctorate in organic chemistry from Iowa State University of Science and Technology followed by a postdoctoral fellowship at the University of Michigan. He has been in the pharmaceutical industry for over 20 years as part of the process development group at Eli Lilly.

Jared has significant technical contributions and leadership across multiple projects as they prepared for commercialization and launch. Jared’s experience spans across both early and late-phase development and includes small molecules, peptides, insulins, and antibody drug conjugates. Currently Jared is leading drug substance development on Lilly’s core innovation portfolio as well as heavily involved with genotoxic impurity risk assessments and controls, regulatory interactions, and authoring of regulatory documents including the CTD drug substance CMC sections.

Related Sessions:

3rd Annual Genotoxic Impurities
in Pharmaceuticals Summit 2023

Genotoxic Impurities in Pharmaceuticals strategies & new methodologies: analysis, in silico & regulations.
  • 09 Mar 2023
  • Virtual,
  • Pharma
Day 2: Friday, 10 March 2023
CASE STUDY: Incorporating Nitrosamine Risk Mitigation Activities Across a Diverse Development Portfolio
View Details